Genetic Susceptibility to Radiation Induced Thyroid Cancer

Thyroid Neoplasms Clinical Trial

Official title:

Genetic Susceptibility to Radiation Induced Thyroid Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04139096
• Other study ID #: C 17-69
• Status: Recruiting
• Start date: September 22, 2019
• Est. completion date: April 30, 2020

Study information

• Verified date: October 2019
• Source: Institut National de la Santé Et de la Recherche Médicale, France
• Contact: Monia Zidane, MD
• Phone: +33142115093
• Email: monia.zidane[@]gustaveroussy.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Case control on thyroid cancer occuring in a cohort of 7300 subjects treated during their childhood, mostly by radiotherapy, for a skin Angioma at Gustave Roussy, Villejuif France between 1947 and 1973.

This case control study, which is included in a larger european project, aims to investigate the DNA variant interacting with the risk of radiation induced thyroid cancer after irradiation.

The sutdy is planed to include about 30 cases and 30 controls. Matching criteria are date of birth, gender, and age at irradiation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: April 30, 2020
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Diganosis of thyroid cancer during the followup or selected as a control matched on gender, date of birth and age at skin hemangioma diagnosis.

Exclusion Criteria:

No available adress Refusal

Related Conditions & MeSH terms

• Disease Susceptibility
• Genetic Predisposition to Disease
• Genetic Susceptibility
• Radiation Exposure
• Thyroid Diseases
• Thyroid Neoplasms

Locations

Country	Name	City	State
France	Gustae Roussy	Villejuif	Val De Marne

Sponsors (1)

Lead Sponsor	Collaborator
Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Differentiated thyroid carcinoma	Number of differentiated thyroid carcinoma occuring in a cohort of subjects treated for a skin hemangioma during the follow-up	From hemangioma diagnosis to the end of the followup, in average 45 years after hemangioma diagnosis